Literature DB >> 10883057

Discordant effect of aspirin and indomethacin on intestinal tumor burden in Apc(Min/+)mice.

C H Chiu1, M F McEntee, J Whelan.   

Abstract

Epidemiologic and animal studies indicate that sustained use of non-steroidal anti-inflammatory drugs (NSAIDs) have a chemopreventive effect against the incidence of colorectal neoplasia and subsequent mortality. We previously demonstrated that sulindac significantly reduces intestinal tumor load in Apc(Min/+)mice and the tumor regression was not necessarily correlated with prostaglandin biosynthesis. In the present study, we further investigate the relationship of NSAID treatment and tumorigenesis in the Apc(Min/+)mouse model. We demonstrate that indomethacin (9 ppm) is a very potent chemopreventive agent, reducing tumor load by 85% and significantly inhibiting basal and ex vivo prostaglandin formation (P< 0.006 and P< 0.0001, respectively). Aspirin (400 ppm) has a similar impact on reducing prostaglandin levels, but in contrast to indomethacin, is uneffective in reducing the tumor load. The data indicate a discordance between the impact of different NSAIDs on tumorigenesis in Apc(Min/+)mice. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10883057     DOI: 10.1054/plef.2000.0154

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  10 in total

1.  Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6-STAT3 signaling pathway.

Authors:  Yun Tian; Ying Ye; Wei Gao; Hong Chen; Ting Song; Daqing Wang; Xiaoyun Mao; Changshan Ren
Journal:  Int J Colorectal Dis       Date:  2010-10-01       Impact factor: 2.571

2.  Supplementation by vitamin D compounds does not affect colonic tumor development in vitamin D sufficient murine models.

Authors:  Amy A Irving; Richard B Halberg; Dawn M Albrecht; Lori A Plum; Kathleen J Krentz; Linda Clipson; Norman Drinkwater; James M Amos-Landgraf; William F Dove; Hector F DeLuca
Journal:  Arch Biochem Biophys       Date:  2011-09-01       Impact factor: 4.013

3.  Lipoprotein lipase as a candidate target for cancer prevention/therapy.

Authors:  Shinji Takasu; Michihiro Mutoh; Mami Takahashi; Hitoshi Nakagama
Journal:  Biochem Res Int       Date:  2011-10-19

4.  Protein kinase A antagonist inhibits β-catenin nuclear translocation, c-Myc and COX-2 expression and tumor promotion in Apc(Min/+) mice.

Authors:  Kristoffer W Brudvik; Jan E Paulsen; Einar M Aandahl; Borghild Roald; Kjetil Taskén
Journal:  Mol Cancer       Date:  2011-12-15       Impact factor: 27.401

5.  Effects of chronic low-dose aspirin treatment on tumor prevention in three mouse models of intestinal tumorigenesis.

Authors:  Nadine Rohwer; Anja A Kühl; Annika I Ostermann; Nicole Marie Hartung; Nils Helge Schebb; Dieter Zopf; Fiona M McDonald; Karsten-H Weylandt
Journal:  Cancer Med       Date:  2020-01-29       Impact factor: 4.452

6.  Age-related difference in susceptibility of Apc(Min/+) mice towards the chemopreventive efficacy of dietary aspirin and curcumin.

Authors:  S Perkins; A R Clarke; W Steward; A Gescher
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

7.  Therapeutic utility of aspirin in the ApcMin/+ murine model of colon carcinogenesis.

Authors:  Brian K Reuter; Xiao-Jing Zhang; Mark J S Miller
Journal:  BMC Cancer       Date:  2002-08-09       Impact factor: 4.430

Review 8.  The proapoptotic effect of traditional and novel nonsteroidal anti-inflammatory drugs in mammalian and yeast cells.

Authors:  Gianluca Farrugia; Rena Balzan
Journal:  Oxid Med Cell Longev       Date:  2013-08-01       Impact factor: 6.543

9.  Bidirectional interactions between indomethacin and the murine intestinal microbiota.

Authors:  Xue Liang; Kyle Bittinger; Xuanwen Li; Darrell R Abernethy; Frederic D Bushman; Garret A FitzGerald
Journal:  Elife       Date:  2015-12-23       Impact factor: 8.140

10.  Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development.

Authors:  Jennifer S Davis; Preeti Kanikarla-Marie; Mihai Gagea; Patrick L Yu; Dexing Fang; Manu Sebastian; Peiying Yang; Ernest Hawk; Roderick Dashwood; Lenard M Lichtenberger; David Menter; Scott Kopetz
Journal:  BMC Cancer       Date:  2020-09-10       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.